Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30322% above fair value
$29.04−0.44 (-1.49%)
Close on Nov 13, 2026Market cap $4.63BP/E –Yield –
Adaptive Biotechnologies profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Adaptive Biotechnologies's profit margin for the twelve months ending Sep 30, 2026 was -23.7%. For fiscal 2025 it was -21.5%, against -89.1% the year before. The highest annual figure on record is -21.5% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -21.5% | +67.6 |
| FY2024 | Dec 31, 2024 | -89.1% | +43.2 |
| FY2023 | Dec 31, 2023 | -132.3% | −24.3 |
| FY2022 | Dec 31, 2022 | -108.0% | +26.3 |
| FY2021 | Dec 31, 2021 | -134.3% | +14.3 |
| FY2020 | Dec 31, 2020 | -148.6% | −68.0 |
| FY2019 | Dec 31, 2019 | -80.6% | +2.8 |
| FY2018 | Dec 31, 2018 | -83.4% | +28.0 |
| FY2017 | Dec 31, 2017 | -111.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 3.4% | −6.7 |
| Q2 FY2026 | Jun 30, 2026 | -55.6% | −12.1 |
| Q1 FY2026 | Mar 31, 2026 | -28.3% | +28.7 |
| Q4 FY2025 | Dec 31, 2025 | -18.9% | +52.0 |
| Q3 FY2025 | Sep 30, 2025 | 10.2% | +79.2 |
| Q2 FY2025 | Jun 30, 2025 | -43.5% | +63.5 |
| Q1 FY2025 | Mar 31, 2025 | -56.9% | +56.5 |
| Q4 FY2024 | Dec 31, 2024 | -71.0% | +80.7 |
| Q3 FY2024 | Sep 30, 2024 | -69.1% | +63.6 |
| Q2 FY2024 | Jun 30, 2024 | -107.0% | −9.3 |
| Q1 FY2024 | Mar 31, 2024 | -113.5% | +39.8 |
| Q4 FY2023 | Dec 31, 2023 | -151.7% | −79.0 |
| Q3 FY2023 | Sep 30, 2023 | -132.7% | −38.0 |
| Q2 FY2023 | Jun 30, 2023 | -97.7% | +21.5 |
| Q1 FY2023 | Mar 31, 2023 | -153.3% | +9.2 |
| Q4 FY2022 | Dec 31, 2022 | -72.7% | +89.3 |
| Q3 FY2022 | Sep 30, 2022 | -94.7% | +47.0 |
| Q2 FY2022 | Jun 30, 2022 | -119.2% | +8.8 |
| Q1 FY2022 | Mar 31, 2022 | -162.4% | −56.7 |
| Q4 FY2021 | Dec 31, 2021 | -162.0% | −14.3 |
| Q3 FY2021 | Sep 30, 2021 | -141.6% | −2.0 |
| Q2 FY2021 | Jun 30, 2021 | -128.0% | +31.7 |
| Q1 FY2021 | Mar 31, 2021 | -105.7% | +44.5 |
| Q4 FY2020 | Dec 31, 2020 | -147.7% | −62.5 |
| Q3 FY2020 | Sep 30, 2020 | -139.6% | −86.1 |
| Q2 FY2020 | Jun 30, 2020 | -159.8% | −89.0 |
| Q1 FY2020 | Mar 31, 2020 | -150.2% | −5.0 |
| Q4 FY2019 | Dec 31, 2019 | -85.1% | −7.9 |
| Q3 FY2019 | Sep 30, 2019 | -53.5% | −5.3 |
| Q2 FY2019 | Jun 30, 2019 | -70.7% | +37.3 |
| Q1 FY2019 | Mar 31, 2019 | -145.2% | – |
| Q4 FY2018 | Dec 31, 2018 | -77.2% | – |
| Q3 FY2018 | Sep 30, 2018 | -48.2% | – |
| Q2 FY2018 | Jun 30, 2018 | -108.0% | – |
See a number that looks wrong?